Progress in Rituximab injection for treatment of refractory nephrotic syndrome in children
10.3969/j.issn.1000-3606.2017.04.019
- VernacularTitle:利妥昔单抗在儿童难治性肾病中的应用进展
- Author:
Xia GAO
;
Li SUN
- Keywords:
Rituximab injection;
Immunosuppressant;
Monoclonal antibody;
Nephrotic syndrome
- From:
Journal of Clinical Pediatrics
2017;35(4):315-318
- CountryChina
- Language:Chinese
-
Abstract:
Glucocorticoid is the first choice for the treatment of nephrotic syndrome in children. But due to various reasons, nephrotic syndrome becomes hormone dependent or resistant, and progresses into refractory nephrotic syndrome in some children, which forces the clinician to constantly look for new immunosuppressants in order to alleviate the condition.,Rituximab injection (RTX) as a monoclonal antibody against CD20 has been widely used in the treatment of a variety of immune diseases in recent years. The use of RTX in refractory nephrotic syndrome in children, its main adverse effects and possible mechanisms was reviewed in this article.